News for MagForce AG (MF6.DE)

The Global Hyperthermia Cancer Treatment Market Size was Valued at USD 187.03 Million in 2023 and the Worldwide Hyperthermia Cancer Treatment Market Size...

Further expansion of management expertise to accelerate BellaSeno´s market entry Leipzig, Germany, April 3, 2024 – BellaSeno GmbH, an ISO...

Statutory Accounts Director's Report In accordance with the Corporations Act 2001, the directors of...

EQS-Ad-hoc: MagForce AG / Key word: Insolvency/Miscellaneous MagForce AG: Agreement in principle on the sale of business operations 14-Nov-2022 / 21:08 CET/CEST Disclosure of an inside... | November 14, 2022

DGAP-News: MagForce AG / Key word(s): Study MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prost...

DGAP-News: MagForce AG / Key word: Study MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the... | November 5, 2021

DGAP-News: MagForce AG / Key word: Study MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal... | November 5, 2021

DGAP-News: MagForce AG / Key word: Half Year Report MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights 28.10.2021 / 08:30 The issuer is solely... | October 28, 2021

The ongoing effects of the COVID-19 pandemic had a noticeable impact on the business of MagForce AG. As a result, revenues could not be increased compared to the previous year and the plans for the... | October 28, 2021

DGAP-News: MagForce AG / Key word: Study MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation... | October 13, 2021